MedTrace Logo

A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma

NCT01949883 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-05-08

No results posted yet for this study

Summary

First in human, open-label, sequential dose escalation and expansion study of CPI-0610 in patients with progressive lymphoma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Conditions

Interventions

DRUG

CPI-0610

Sponsors & Collaborators

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • Constellation Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-05
Primary Completion
2017-12-20
Completion
2017-12-20

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01949883 on ClinicalTrials.gov